Advertisement
Canada markets open in 2 hours 10 minutes

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7288
    +0.0007 (+0.09%)
     

  • CRUDE OIL

    79.35
    +0.35 (+0.44%)
     

  • Bitcoin CAD

    79,884.95
    +830.15 (+1.05%)
     

  • CMC Crypto 200

    1,258.14
    -12.60 (-0.99%)
     

  • GOLD FUTURES

    2,311.10
    +0.10 (+0.00%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,606.00
    +167.75 (+0.96%)
     

  • VOLATILITY

    14.98
    -0.41 (-2.66%)
     

  • FTSE

    8,153.61
    +32.37 (+0.40%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6807
    +0.0014 (+0.21%)
     

Ionis to hold olezarsen Phase 3 data webcast

PR Newswire
·1 min read

Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time

CARLSBAD, Calif., March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.

Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)
Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

ADVERTISEMENT

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-olezarsen-phase-3-data-webcast-302101842.html

SOURCE Ionis Pharmaceuticals, Inc.